3 Top Growth Plays That Could Smash The FTSE 100: ARM Holdings plc, GlaxoSmithKline plc & Diageo plc

Though the FTSE 100 (INDEXFTSE:UKX) could go much higher, ARM Holdings plc (LON:ARM), GlaxoSmithKline plc (LON:GSK) & Diageo plc (LON:DGE) could beat it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE100

With the S&P 500 hitting record highs, 2014 has been something of a disappointment for the FTSE 100. Indeed, the index is up just 1% since the turn of the year, but does seem to have huge potential over the medium term. That’s because it trades on a price to earnings (P/E) ratio of just 13.8 and has a yield of around 3.5% — both of which indicate that the index could push northwards.

However, here are three shares that despite the FTSE 100’s potential, could still outperform the UK’s main index.

ARM

Although shares in ARM (LSE: ARM) have fallen by 12% during the course of 2014, the intellectual property business could beat the FTSE 100 going forward. That’s because it offers investors a vast amount of growth potential, with the company’s earnings per share (EPS) expected to increase by an impressive 23% in 2015. Furthermore, with shares in ARM having fallen, they now represent much better value for money. Indeed, although ARM’s price to earnings (P/E) ratio remains high at 41.5, its price to earnings growth (PEG) ratio of just 1.5 means that it could outperform the FTSE 100 over the medium term.

GlaxoSmithKline

As with ARM, 2014 has been a tough year for GlaxoSmithKline (LSE: GSK). Its shares have dropped by 9% and the company continues to suffer from weak sentiment due to bribery allegations. However, GlaxoSmithKline also has a highly diversified and capable drugs pipeline that has the potential to deliver brisk earnings growth in future years. Certainly, all drug pipelines come with a large dollop of uncertainty, but GlaxoSmithKline appears to have a well-balanced pipeline that should benefit from a renewed focus by the company after the sale of its consumer brands. In the meantime, a yield of 5.6% should help to push investors’ total return above that of the FTSE 100.

Diageo

Diageo (LSE: DGE) is also down in 2014, with the alcoholic beverages company seeing its share price fall by 12% year-to-date. However, demand for premium alcoholic drinks should remain robust in the long run – even if the world economy does fall back into negative growth territory. Moreover, Diageo’s strong stable of brands should ensure that demand for its products remains buoyant in developed nations, while emerging markets such as China and India present a huge opportunity for the company to increase its sales and profitability. As a result, it could have a much brighter future and has the scope to beat the main index moving forward.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended shares in GlaxoSmithKline and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£9,000 in savings? Here’s how to try and turn that into a £193 monthly second income

With a long-term approach and applying basic principles of good investment, our writer reckons someone with under £10k could earn…

Read more »

Investing Articles

A 2026 stock market crash could be a rare passive income opportunity

If a stock market crash comes our way then it might throw up plentiful opportunities for investors to secure a…

Read more »

Tesla car at super charger station
Investing Articles

£10,000 invested in Tesla stock 1 year ago is now worth…

Dr James Fox takes a closer look at Tesla stock with the incredibly volatile mega-cap company surging and pulling back…

Read more »

British pound data
Investing Articles

My personal warning for anyone tempted by the plunging Aston Martin share price

Harvey Jones was so captivated by the plunging Aston Martin share price that he ignored an old piece of investment…

Read more »

Stacks of coins
Investing Articles

This penny share just crashed 13% to 19p! Time to buy?

After another fall today, this penny stock has now crashed 70% since April 2021. Is it one that should be…

Read more »

Trader on video call from his home office
Investing Articles

Down 19%! Here’s why Barclays shares look a serious bargain to me right now

Barclays shares have slumped recently, but a big gap between price and fair value has opened, offering nimble long-term investors…

Read more »

CEO Mark Zuckerberg at F8 2019 event
Investing Articles

Why Meta Platforms shares fell 12.5% in March

Historically, investors have done well by buying Meta Platforms shares when the price has fallen. But is the latest legal…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£20,000 invested in BAE Systems shares 4 years ago is now worth…

BAE Systems' shares have soared since 2022, yet rising NATO budgets are just starting to feed through, so the real…

Read more »